retatrutide for women side effects Lilly's shows 28% weight loss, but increased Retatrutide Side Effects: What Research

This positions amycretin as a direct competitor to retatrutide, likely reaching market around the same time

Retatrutide is a triple agonist (GLP-1, GIP, and glucagon receptors), which makes it considerably more powerful than semaglutide or even tirzepatide

Management strategies for gastrointestinal effects focus on dietary modifications and gradual dose escalation

GLP-1 agonists are generally considered low risk for hypoglycemia because their insulinotropic effects are glucose-dependent, tapering off as serum glucose approaches euglycemia

In contrast, adults aged 45 to 54 make up just 16.1% of the obesity population, but comprise 24.3% of GLP-1 users